According to court documents, the lawsuits focus on Moderna's use of lipid nanoparticle encapsulation of mRNA vaccines, a technology used to protect the mRNA molecules as they are delivered to ...

Meanwhile, Alnylam has filed suit against both Pfizer/BioNTech and Moderna in the US, alleging that both their vaccines infringe patents it holds on lipid nanoparticles used to deliver them in the ...

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Genevant Sciences and Arbutus Biopharma have filed five international lawsuits against Moderna Inc. to enforce patents related to their lipid nanoparticle (LNP) technology, which is used in ...

Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded ...

A novel strategy using lipid nanoparticles to reprogram liver immunity shows promise in generating antitumor responses ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

Notable examples include the Pfizer-BioNTech and Moderna vaccines, which rely on lipid nanoparticles (LNPs) for mRNA protection and cellular uptake, and hepatitis B vaccines, which use virus-like ...

March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle ... against Moderna, Inc. and certain ...

Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax ® and, where applicable, additional Moderna products that Moderna ... company with world-class platforms, a robust ...